Celgene Corp. PT Raised to $170.00 at RBC Capital (CELG)
Equities researchers at RBC Capital increased their price target on shares of Celgene Corp. (NASDAQ:CELG) from $150.00 to $170.00 in a research report issued on Wednesday, ARN reports. The firm currently has an “outperform” rating on the stock. RBC Capital’s price objective indicates a potential upside of 15.75% from the company’s current price.
Other equities research analysts have also recently issued reports about the stock. Analysts at Bank of America Corp. raised their price target on shares of Celgene Corp. from $164.00 to $179.00 in a research note to investors on Tuesday. They now have a “buy” rating on the stock. Separately, analysts at TheStreet reiterated a “buy” rating on shares of Celgene Corp. in a research note to investors on Monday. Finally, analysts at Leerink Swann raised their price target on shares of Celgene Corp. from $165.00 to $177.00 in a research note to investors on Wednesday, September 25th. They now have an “outperform” rating on the stock. Six analysts have rated the stock with a hold rating and twenty-four have issued a buy rating to the company’s stock. Celgene Corp. presently has a consensus rating of “Buy” and an average target price of $145.15.
Celgene Corp. (NASDAQ:CELG) traded down 1.12% during mid-day trading on Wednesday, hitting $146.87. 5,363,220 shares of the company’s stock traded hands. Celgene Corp. has a one year low of $71.23 and a one year high of $157.95. The stock has a 50-day moving average of $147.2 and a 200-day moving average of $130.9. The company has a market cap of $60.404 billion and a price-to-earnings ratio of 41.54.
Celgene Corp. (NASDAQ:CELG) last announced its earnings results on Thursday, July 25th. The company reported $1.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.44 by $0.08. The company had revenue of $1.56 billion for the quarter, compared to the consensus estimate of $1.54 billion. During the same quarter in the previous year, the company posted $1.22 earnings per share. The company’s revenue for the quarter was up 17.0% on a year-over-year basis. Analysts expect that Celgene Corp. will post $5.97 EPS for the current fiscal year.
Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.